RecruitingNot Applicable

Effect of Sarcopenia and Frailty on Rocuronium Pharmacodynamics in Geriatric Patients

Turkey (Türkiye)100 participantsStarted 2026-05-13

Plain-language summary

This prospective observational study aims to evaluate whether sarcopenia and frailty affect the pharmacodynamic profile of rocuronium in geriatric patients undergoing elective surgery under general anesthesia.

Who can participate

Age range

65 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Scheduled to undergo elective surgery under general anesthesia requiring endotracheal intubation * Planned use of rocuronium for neuromuscular blockade * Quantitative neuromuscular monitoring planned during anesthesia * American Society of Anesthesiologists physical status I-III * Ability to provide written informed consent * Completion of preoperative frailty and sarcopenia assessment Exclusion Criteria: * Emergency surgery * Known neuromuscular disease * History of allergy or contraindication to rocuronium, sugammadex * Severe hepatic insufficiency * Severe renal insufficiency * Use of drugs known to significantly affect neuromuscular transmission * Preoperative mechanical ventilation or intensive care unit admission * Inability to perform a frailty or sarcopenia assessment * Patients in whom quantitative neuromuscular monitoring cannot be properly performed * Refusal to participate in the study

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Rocuronium onset time

Timeframe: Perioperative/Periprocedural - during anesthesia induction

Trial details

NCT IDNCT07580144

SponsorKonya Meram State Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08-01

Contact for this trial

Betül kozanhan, M.D.

05055044808 betulkozanhan@gmail.com

View on ClinicalTrials.gov More Sarcopenia trials

Who can participate

Age range

65 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.